Early initiation of SGLT2 inhibitors within guideline-directed medical therapy and outcomes in newly diagnosed heart failure patients (vol. 25, 879, 2025)
JavaScript is disabled for your browser. Some features of this site may not work without it.
Early initiation of SGLT2 inhibitors within guideline-directed medical therapy and outcomes in newly diagnosed heart failure patients (vol. 25, 879, 2025)